Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
104 results about "Phenylacetones" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Phenylacetones are a group of organic compounds containing a phenyl moiety and an acetone moiety bonded together, the archetypal example being phenylacetone. Phenylacetones often play a role in the illicit synthesis of amphetamine and its analogues, 3,4-methylenedioxyphenyl-2-propanone (MDP2P) for example being used in the production of 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxy-N-ethylamphetamine (MDEA), and other homologues.
A genetically engineered bacterium producing 2-phenylethanol and an applying method thereof
ActiveCN106566794AImprove cycle efficiencyDisinhibitionBacteriaMicroorganism based processesPhenethyl alcoholPhenylpyruvate decarboxylase
A genetically engineered bacterium producing 2-phenylethanol and an applying method thereof are disclosed. The recombinant bacterium is constructed by coexpressing aromatic amino acid aminotransferase and exogenous phenylpyruvate decarboxylase (Aro10) (or indole-3-pyruvic acid decarboxylase), phenylethanol dehydrogenase or phenylacetaldehyde reductase in escherichia coli to obtain the recombinant bacterium producing the 2-phenylethanol. Glutamate dehydrogenase is coexpressed on this basis to achieve self-balancing cofactor circulation, thus increasing the yield of the 2-phenylethanol. The conversion ratio of the 2-phenylethanol prepared through the recombinant bacterium is high. The bacterium and the method have important application value in production of the 2-phenylethanol in the future.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
MRNA therapy for phenylketonuria
ActiveUS9522176B2Efficient productionEffective treatmentNervous disorderSugar derivativesLipofectaminePhenylalanine hydroxylase cofactor
The present invention provides, among other things, methods of treating phenylketonuria (PKU), including administering to a subject in need of treatment a composition comprising an mRNA encoding phenylalanine hydroxylase (PAH) at an effective dose and an administration interval such that at least one symptom or feature of PKU is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.
Owner:TRANSLATE BIO INC
Novel dehydrogenase and a gene encoding the same
InactiveUS20050124040A1Generate efficientlyEfficient productionFungiBacteriaPhenylpyruvic acidPyruvic acid acetal
The object of the present invention is to provide a novel dehydrogenase having a property which is different from that of known dehydrogenases. The present invention provides a dehydrogenase having the following physicochemical properties: (1) effect: to produce N-alkyl-L-alanine from pyruvic acid and alkylamine or dialkylamine using NADPH and / or NADH as coenzyme; (2) substrate specificity: to show activity to alkylamine or dialkylamine but not to ammonium; (3) optimal pH when using phenylpyruvic acid and methylamine as substrates is around 10; and (4) when treated at 30° C. for 30 minutes, the enzyme is stable at around pH 5 to 10.5.
Owner:MITSUBISHI CHEM CORP
Compositions and methods for the treatment of metabolic diseases
InactiveUS20150291590A1Treat and prevent and ameliorate effectOrganic chemistryNephrosisEndothelial dysfunction
The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III; and methods for treating or preventing metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of phenylketonuria, cardiovascular disease, autism, ADHD, hypertension, endothelial dysfunction and chronic kidney disease.
Owner:CELLIXBIO PTE LTD
Method for preparing chiral monomer mandelic acid
InactiveCN102086462AIn line with the development directionImprove sustainabilityBacteriaMicroorganism based processesPhenylpyruvic acidPara-hydroxymandelic acid
The invention provides a method for preparing S-mandelic acid or R-mandelic acid and a method for converting S-mandelic acid into R-mandelic acid. The method comprises the following steps: catalyzing phenylpyruvic acid by using p-hydroxymandelic acid synthetase or mandelic acid synthetase to obtain S-mandelic acid; and catalyzing the S-mandelic acid by using p-hydroxymandelic acid oxidase or mandelic acid oxidase or mandelic acid dehydrogenase, and D-mandelic acid dehydrogenase or D-mandelic acid reductase to obtain R-mandelic acid. The method provided by the invention can be used for in-vitro preparation of single-configuration S-mandelic acid or R-mandelic acid; meanwhile, the enzymes can be combinedly over-expressed to ferment glucose, thereby obtaining S-mandelic acid or R-mandelic acid; and the method can be used for chirally splitting DL-mandelic acid to generate R-mandelic acid or S-mandelic acid, or converting S-mandelic acid into R-mandelic acid. When being used for synthesizing S-mandelic acid or R-mandelic acid by fermentation and culture, the method is sustainable and can lower the cost; and in addition, the method is mild, and friendly to environment and human.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Production of L phenylalanine gene engineering bacteria and construction method and its application
InactiveCN1757737AReduce manufacturing costLow costFermentationVector-based foreign material introductionPhosphopyruvate carboxykinasePlasmid
A genetically engineered bacterium for preparing L-Phe is prepared from transaminase gene and constitutive promoter through linking, and inserting them into carrier to configure constitutive expression plasmid. The L-Phe can be prepared through converting the phenylphruvic acid in proper host bacteria by relative said genetically engineered bacterium. It has high mole conversion rate.
Owner:NANJING UNIV OF TECH
Method and apparatus for examining diseases with inborn errors of metabolism
InactiveCN1461347AEasy to operateAvoid the need to prepare reagentsMicrobiological testing/measurementBiological testingTert-leucinePhenylalanine
A method of conveniently and quickly quantitating subject substances which comprises using as reaction reagents at least dehydrogenases specific respectively to branched amino acids containing D-galactose and L-leucine and phenylalanine, which are the substances contained in biological samples to be assayed, coenzymes, an electron mediator and a tetrazolium salt and detecting formazan, which has been finally formed depending on the concentrations of the subject substances by the enzymatic reactions and oxidation reactions of the biological samples with the reaction reagents, by using both or one of an optical detection procedure and an electrochemical detection procedure, thereby embodying a convenient and quick examination of three diseases with inborn errors of metabolism, i.e., galactosemia, maple syrup urine disease and phenylketonuria.
Owner:SAPPORO IMMUNO DIAGNOSTIC LAB
Technology for producing phenylpyruvic acid by phenylalanine through enzymatic conversion
ActiveCN109022338AThe conversion system is simpleEasy to purifyBacteriaMicroorganism based processesPhenylpyruvic acidBio engineering
The invention discloses a technology for producing phenylpyruvic acid by phenylalanine through enzymatic conversion and belongs to the technical field of biological engineering. According to the technology disclosed by the invention, a proteus mirabilis derived amino acid deaminase mutant is subjected to codon optimization and fermentation condition optimization and the enzyme activity of amino acid deaminase is remarkably improved. Furthermore, a conversion condition is optimized and the yield of the phenylpyruvic acid is remarkably improved; when the adding amount of wet strains is 25 to 30g / L, the yield of the phenylpyruvic acid can reach 81.1 to 83.0g / L and the mol conversion rate of the phenylpyruvic acid reaches 98.0 percent or mor.
Owner:JIANGNAN UNIV +1
Compound with dual restraining activities to acetyl cholinesterase and butyryl cholinesterase and use thereof
The invention adopts a virtual medicine screening technology and a high-throughput screening technology, assesses the AChE inhibitory activity of more than ten thousand samples in a compound sample library and finds a batch of compounds with higher inhibitory activity by establishing a virtual acetylcholinesterase inhibitor screening method and an AChE activity detection method. Then according to the pathological features of senile dementia, the compounds with higher AChE inhibitory activity are subject to butyryl choline esterase inhibitory activity detection. Research results show that bimolecular 3-piperidyl-ethyl phenyl ketone not only has comparatively high AChE inhibitory activity, but also has very strong BuChE inhibitory activity; the results of animal experiments prove that the bimolecular 3-piperidyl-ethyl phenyl ketone can remarkably improve aphronesia caused by scopolamine and sodium nitrite and can enhance the ability of learning and memory.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Method for preparing bupropion hydrochloride
InactiveCN105968023AAvoid damageReduce pollutionOrganic chemistryOrganic compound preparationTert-ButylamineAlcohol
The invention discloses a novel method for preparing bupropion hydrochloride. According to the invention, m-chlorophenylacetone is taken as an initiator, then is brominated in a hydrobromic acid-hydrogen peroxide system, 3'-chlorine-alpha-bromophenyl ethyl ketone is synthesized; then through replacement by tert-butylamine and acidification by HCl-absolute ethyl alcohol, bupropion hydrochloride is obtained. The preparation method of bupropion hydrochloride replaces traditional bromine bromination, pollution can be effectively reduced, damage due to bromine volatilization on the operators can be greatly mitigated, and the method has the advantages of simple operation, low cost, high yield, and less side reaction, and is very suitable for industrial production.
Owner:WEIHAI DISU PHARMA CO LTD
Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
Owner:BIOMARIN PHARMA INC
Mutant of phenylalanine deaminase with anabaena source
InactiveCN106497905ACope wellGood pH stabilityCarbon-nitrogen lyasesNervous disorderOral medicationProtein engineering
The invention discloses a mutant of phenylalanine deaminase with an anabaena source and belongs to protein engineering. The phenylalanine deaminase E75L obtained in the invention has trypsin degradation resistance and low pH resistance which are greatly improved compared with those of wild-type enzymes. The phenylalanine deaminase E75L provided by the invention achieves the effect of promoting application of the phenylalanine deaminase in oral medication of phenylketonuria (PKU) to a certain degree.
Owner:JIANGNAN UNIV
Composition for preventing or/and treating insulin resistance and related diseases
The invention relates to metabolism of enteric microorganisms and phenylalanine and phenylpyruvic acid of the enteric microorganisms, and provides a composition containing phenyllactic acid or salts of phenyllactic acid and phenylpyruvic acid or salts of phenylpyruvic acid and used for preventing or / and treating insulin resistance and related diseases, use of the composition in preparation of a medicine or food for improving, preventing or treating insulin resistance and related diseases, and a method for preventing or treating insulin resistance and related diseases. The related diseases include intestinal dysbacteriosis, metabolic syndrome, obesity, diabetes, podagra and tumors.
Owner:萧湘
Method for preparing dapoxetine intermediate by using carbonyl reductase
InactiveCN111378694AReduce usageMild reaction conditionsOxidoreductasesFermentationChlorobenzenePtru catalyst
The invention discloses a method for preparing dapoxetine intermediate by using carbonyl reductase. In the method, a crushed mixed solution of wet cells obtained by induction culture of engineered bacteria containing the carbonyl reductase gene after ultrasonication is used as a catalyst, and 3-chlorophenylacetone is used as a substrate, and NADH and isopropanol are added, and a phosphate buffer with a pH of 6.5. -7.5 is used as a reaction medium to constitute a reaction system. The reaction system is complete with magnetic stirring at 30-40 DEG C. The reaction solution is separated and purified to obtain (R)-3-chlorophenylpropanol. The invention adopts a new type of carbonyl reductase to catalyze a reduction reaction, has the advantages of small amount of biocatalyst, mild reaction conditions (30-40 DEG C), short reaction time (6-12 hours), 95.2% of yield coefficient, and good optical purity (greater than 99), and the like.
Owner:ZHEJIANG UNIV OF TECH
Method for synthetizing D-phenyllactic acid through recombinant Escherichia coli
InactiveCN104099350AIncrease productionHigh affinityBacteriaMicroorganism based processesEscherichia coliNucleotide
The invention relates to a recombinant lactate dehydrogenase gene. The nucleotide sequence of the gene is represented by SEQ ID NO:1, and tyrosine is mutated into any one of alanine, valine and leucine in the 52 position of the sequence. The invention further relates to recombinant Escherichia coli containing the recombinant lactate dehydrogenase gene and a method for synthetizing D-phenyllactic acid through the recombinant Escherichia coli. According to the method, the tyrosine on a substrate recognition site of D-LDH is replaced by smaller hydrophobic amino acid residue-valine with a site-directed mutagenesis technology, so that the affinity and the catalytic efficiency of the D-LDH to substrate phenylpyruvic acid are improved, after conversion of an expression host, the yield of phenyllactic acid is significantly increased when being compared with that of un-mutated strains, and after whole-cell conversion for 6 h, the yield of the phenyllactic acid is increased from 18 g / L to 24.6 g / L.
Owner:CHANGSHU INSTITUTE OF TECHNOLOGY
Multi-level hole function support material for mobilization endogenous neural stem cell repair spinal cord injuries and preparation method and application thereof
ActiveCN110101918AFacilitate directed migrationImprove motor functionTissue regenerationProsthesisNeural stem cellDouble bond
The invention relates to a multi-level hole function support material for mobilization endogenous neural stem cell repair spinal cord injuries and a preparation method and application thereof. The preparation method of the material comprises the steps that modified double-bounded chitosan is mixed with a cross-linking agent BIS, 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one anddistilled water to obtain a precursor solution, growth factors are added or not added to prepare a glue precursor solution, the precursor solution is placed into liquid nitrogen for ice crystal guiding,guiding, and then under ultraviolet irradiation at the temperature of subzero 20 DEG C, glue is formed by initiation. The material is provided with guiding holes of different sizes in the inner diameter of the long axis of the material, the space structure needed by neural circuit reconstruction is supplied, endogenous neural stem cells can be directionally migrated to the material transplanting region conveniently to form new born nerve cells, a neural network is formed by multi-level structure growth designed at the nerve synapse edge, the neural circuit at the injured region is rebuilt,and the motor function recovery after spinal cord injuries is promoted.
Owner:SHANGHAI TONGJI HOSPITAL +1
Engineering probiotic with surface display phenylalanine ammonia lyase
PendingCN112662607AEfficient degradationBacteriaPeptide/protein ingredientsEscherichia coliPhenylalanine transport
The invention discloses an engineering probiotic capable of displaying phenylalanine ammonialyase on the surface, which is an escherichia coli Nissle 1917 derived bacterium, a gene argR is knocked out and / or a gene argA (Y19C) mutation is generated on a genome, and an L-phenylalanine ammonialyase gene stlA, an L-phenylalanine transport protein gene pheP, an L-amino acid deaminase gene pma and an efflux pump gene acrA are integrated. The engineering probiotics can be used for treating phenylketonuria.
Owner:SHANGHAI TAOYUSHENG BIOTECHNOLOGY CO LTD
Greasy dirt cleaning agent
InactiveCN104928075AEasy to cleanSimple compositionDetergent compounding agentsOrganic non-surface-active detergent compositionsMethyl benzeneEthylic acid
The invention discloses a greasy dirt cleaning agent which comprises the following components in percentage by weight: 10-20% of diethyl benzylamine, 10-30% of n-butyl acetate, 30-40% of ethyl methyl benzene and 20-40% of acetone. The components interwork to constitute the cleaning agent capable of cleaning greasy dirt conveniently; the greasy dirt cleaning agent is simple in composition and excellent in cleaning effect.
Owner:LIUZHOU LIJIE TECH
Perovskite thin film and anti-solvent preparation method of photoelectric detector containing perovskite thin film
PendingCN113809239AFast preparationImprove photoelectric performanceSolid-state devicesSemiconductor/solid-state device manufacturingChlorobenzeneSolvent
The invention belongs to the technical field of photoelectric detectors, and discloses a perovskite thin film and an anti-solvent preparation method of a photoelectric detector containing the perovskite thin film. The preparation method of the anti-solvent comprises the following steps: (1) placing a substrate in plasma cleaning equipment for modification treatment to obtain a modified substrate; and (2) heating the modified substrate prepared in the step (1), dropwise adding a perovskite precursor solution on the modified substrate, dropwise adding an anti-solvent, reacting and annealing to prepare a perovskite thin film, wherein the anti-solvent comprises at least one of methylbenzene, acetone, chlorobenzene or chloroform; and the annealing temperature is 78-122 DEG C. The photoelectric detector has good photoelectric performance and also has high responsivity, external quantum efficiency and specific detection rate, the responsivity of the photoelectric detector is 200-700 [mu] A / W, the external quantum efficiency is greater than 0.01, and the specific detection rate is 108-109 Jones.
Owner:佛山仙湖实验室
Rapid test and identification method for organic mixed liquid sample and application
PendingCN114088957AQuickly achieve ingredient identificationEasy and quick passComponent separationMaterial analysis by optical meansAssayPhysical chemistry
The invention provides a rapid test and identification method for an organic mixed liquid sample. The rapid test and identification method comprises the following steps: (1) qualitative analysis: 1) infrared spectroscopy qualitative analysis; (2) carrying out qualitative analysis by using a gas chromatography-mass spectrometry method; (2) when the qualitative analysis result in the step (1) shows that the sample contains one or more of toluene, acetone and butanone, further quantitatively analyzing the contents of toluene, acetone and butanone, wherein when the qualitative analysis result in the step (1) shows that the sample does not contain any one of toluene, acetone and butanone, the step (2) does not need to be carried out. The method has the following beneficial effects: (1) the pretreatment conditions are simple and rapid, and complicated extraction, purification and other means are not needed; (2) the method has strong universality and is suitable for various organic mixed liquid samples; and (3) component identification of the organic mixed liquid sample can be rapidly realized, rapid customs clearance of enterprises is facilitated, and customs are served for law enforcement and customs control.
Owner:INSPECTION & QUARANTINE TECH CENT SHANDONG ENTRY EXIT INSPECTION & QUARANTINE BUREAU
Polymorphs of sepiapterin and salts thereof
ActiveUS11072614B2Diminishment of extentImprove clinical outcomesOrganic active ingredientsNervous disorderDiseasePterin
Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria.
Owner:PTC THERAPEUTICS MP INC
Medicago sativa hydroxyphenylpyruvic acid dioxygenase gene and application
ActiveCN105505956AIncreased E contentIncrease contentOxidoreductasesFermentationNucleotideArabidopsis
The invention discloses a medicago sativa hydroxyphenylpyruvic acid dioxygenase gene MsHPPD. The nucleotide sequence of the dioxygenase gene is as shown in SEQID NO:1 in a sequence table. The invention also discloses a primer pair for cloning the medicago sativa hydroxyphenylpyruvic acid dioxygenase gene MsHPPD, and nucleotide sequences are as shown in the SEQ IDNO:4 and SEQID NO:5 in the sequence table respectively. The invention further discloses a preparation method of the medicago sativa hydroxyphenylpyruvic acid dioxygenase gene MsHPPD, and the application of the medicago sativa hydroxyphenylpyruvic acid dioxygenase gene MsHPPD in the increase of the content of vitamin E in arabidopsis thaliana and improving the stress resistance. According to the medicago sativa hydroxyphenylpyruvic acid dioxygenase gene MsHPPD disclosed by the invention, a base is established for further research on functions of the medicago sativa MsHPPD gene, and the application of the MsHPPD gene in the improvement on the quality of pasture, particularly the application of the MsHPPD gene in the increase of the content of the vitamin E in molecular improved pasture.
Owner:INST OF ANIMAL SCI OF CHINESE ACAD OF AGRI SCI
Glycomacropeptide medical foods for nutritional management of phenylketonuria and other metabolic disorders
InactiveUS20130196024A1Increase dietary compliance and quality of lifeNervous disorderFruit and vegetables preservationComplete proteinArginine
Owner:WISCONSIN ALUMNI RES FOUND
Meso-diaminopimelic acid dehydrogenase mutants with improved catalytic efficiency
ActiveCN110499301AHigh catalytic activityHigh catalytic efficiencyBacteriaMicroorganism based processesEscherichia coliMeso-diaminopimelic acid
The invention discloses meso-diaminopimelic acid dehydrogenase mutants with improved catalytic efficiency, and belongs to the technical field of gene engineering. According to the invention, single-site / double-site mutation is carried out on meso-diaminopimelic acid dehydrogenase shown as SEQ ID NO.2, and mutant enzymes D94A, W123K, D94A / W123K and W148K are successfully expressed and purified in escherichia coli. Enzyme activity measurement finds that the three meso-diaminopimelic acid dehydrogenase mutants have higher catalytic activity than the wild type, for example, the efficiencies of catalyzing phenylpyruvic acid by the mutant enzymes DAPDH-D94A, DAPDH-W123K and DAPDH-D94A / W123K are respectively improved by 3.5 times, 1.5 times and 1.3 times, and the enzyme activity of key enzymes issuccessfully improved.
Owner:JIANGNAN UNIV
Microencapsulated saccharomyces and its application
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Pharmaceutical compositions comprising sepiapterin and uses thereof
PendingUS20200061070A1Improve propertiesImprove bioavailabilityPowder deliveryOrganic active ingredientsDiseasePterin
The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and / or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.
Owner:PTC THERAPEUTICS MP INC
Method of preparing chiral phenylalanine by catalysis and asymmetric reduction of marine strain
ActiveCN104152384AImprove responseOptimizationBacteriaMicroorganism based processesBacillus nanhaiensisFermentation
The invention discloses a method of preparing chiral phenylalanine by catalysis and asymmetric reduction of a marine strain, and relates to chiral phenylalanine. Bacillus nanhaiensis DSP-15A2 is preserved in CGMCC (China General Microbiological Culture Collection Center) with a preservation number of CGMCC No. 8969. The method comprises the steps of adding the bacillus nanhaiensis to a 2216L culture medium for culture to obtain a fermentation solution, centrifuging to obtain a cell, resuspending and washing with a buffer solution, preparing a cell solution, adding phenylpyruvic acid and an amino donor to the cell solution as substrates, adding an auxiliary substrate for cyclic regeneration of coenzyme, performing a reaction to obtain a reaction solution containing a product namely L-phenylalanine, centrifuging to remove deposit, adding equivalent methanol to a supernate, shaking and mixing uniformly, centrifuging to remove deposit (protein), diluting the supernate, then measuring, detecting the concentration of phenylpyruvic acid by high performance liquid chromatography, and measuring the concentration of the product namely L-phenylalanine and an excessive value of an antipode by the high performance liquid chromatography.
Owner:XIAMEN UNIV
Separated polypeptide and application thereof
The invention relates to a separated polypeptide, a separated oligonucleotide, an expression vector, a microorganism, a preparation method for the microorganism, a preparation method for aromatic amino acid transaminase and a preparation method for phenylpyruvic acid. The separated polypeptide is provided with an amino acid sequence shown in SEQ ID NO:2. The polypeptide has activity of aromatic amino acid transaminase.
Owner:CHANGSHU INSTITUTE OF TECHNOLOGY
Fecal biomarker for diagnosing or preventing diabetes mellitus, detection reagent and application of fecal biomarker
PendingCN114324711AGood forecastStrong specificityComponent separationOXALIC ACID DIHYDRATEAklanonic acid
The invention relates to a fecal biomarker for diagnosing or preventing diabetes mellitus, a detection reagent and application of the fecal biomarker. The excrement biomarker for diagnosing or preventing diabetes mellitus provided by the invention comprises one or more of 2-hydroxyhexanoic acid, phenylalanine, valine, acetyltryptophan, nonadecanoic acid, oxalic acid, picolinic acid, alpha-hydroxyisobutyric acid, indoleacetic acid, p-hydroxyphenylacetic acid, acetic acid, thyroxine, 4-hydroxyphenylpyruvic acid, myristic acid or phenylacetic acid. The fecal biomarker provided by the invention is high in sensitivity and specificity and good in predictability, and can be used for early diagnosis or prevention of diabetic people, especially diabetic people exposed by combination of long-term low-dose radiation and high-glucose and high-fat diet.
Owner:CENT SOUTH UNIV
Water-solubility polyphenylene sulfide and preparation method thereof
InactiveCN101885843BBreak the rule of being insoluble in any solventGuaranteed ability to resist low molecular electrolytesPyrrolidinonesPhenylacetones
Owner:SICHUAN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com